Duke Transplant Center, Duke University School of Medicine, Durham, NC 27710, USA.
Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Sci Transl Med. 2024 Jun 12;16(751):eadk6152. doi: 10.1126/scitranslmed.adk6152.
Genetic modification of porcine donors, combined with optimized immunosuppression, has been shown to improve outcomes of experimental xenotransplant. However, little is known about outcomes in sensitized recipients, a population that could potentially benefit the most from the clinical implementation of xenotransplantation. Here, five highly allosensitized rhesus macaques received a porcine kidney from (α1,3-galactosyltransferase) knockout pigs expressing the human transgene (1KO.1TG) and were maintained on an anti-CD154 monoclonal antibody (mAb)-based immunosuppressive regimen. These recipients developed de novo xenoreactive antibodies and experienced xenograft rejection with evidence of thrombotic microangiopathy and antibody-mediated rejection (AMR). In comparison, three highly allosensitized rhesus macaques receiving a kidney from , (cytidine monophospho--acetylneuraminic acid hydroxylase), and / (β-1,4--acetyl-galactosaminyltransferase 2) knockout pigs expressing seven human transgenes including human , , , (thrombomodulin), (protein C receptor), (tumor necrosis factor-α-induced protein 3), and (heme oxygenase 1) (3KO.7TG) experienced significantly prolonged graft survival and reduced AMR, associated with dampened post-transplant humoral responses, early monocyte and neutrophil activation, and T cell repopulation. After withdrawal of all immunosuppression, recipients who received kidneys from 3KO.7TG pigs rejected the xenografts via AMR. These data suggest that allosensitized recipients may be suitable candidates for xenografts from genetically modified porcine donors and could benefit from an optimized immunosuppression regimen designed to target the post-transplant humoral response, thereby avoiding AMR.
基因修饰的猪供体与优化的免疫抑制相结合已被证明可改善实验性异种移植的结果。然而,对于致敏受者的结果知之甚少,而这群人最有可能从异种移植的临床实施中受益。在这里,五只高度同种致敏的恒河猴接受了来自 (α1,3-半乳糖基转移酶)基因敲除猪的猪肾脏,这些猪表达了人类 基因(1KO.1TG),并接受了抗 CD154 单克隆抗体(mAb)为基础的免疫抑制方案。这些受者产生了新的异种反应性抗体,并经历了异种移植物排斥反应,表现为血栓性微血管病和抗体介导的排斥反应(AMR)。相比之下,三只高度同种致敏的恒河猴接受了来自 , (胞苷单磷酸--乙酰神经氨酸羟化酶)和 / (β-1,4--乙酰-半乳糖胺基转移酶 2)基因敲除猪的肾脏,这些猪表达了包括人类 、 、 (血栓调节蛋白)、 (蛋白 C 受体)、 (肿瘤坏死因子-α诱导蛋白 3)和 (血红素加氧酶 1)在内的七个人类基因(3KO.7TG),移植后受者的移植物存活时间显著延长,AMR 减少,与移植后体液反应减弱、单核细胞和中性粒细胞早期激活以及 T 细胞再定植有关。在撤除所有免疫抑制剂后,接受 3KO.7TG 猪肾脏的受者通过 AMR 排斥了异种移植物。这些数据表明,同种致敏受者可能是基因修饰猪供体异种移植物的合适候选者,并可能受益于旨在靶向移植后体液反应的优化免疫抑制方案,从而避免 AMR。